Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

BACKGROUND: Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (MBC) accounts for 73% of all MBCs. Endocrine therapy (ET) is the basis of first-line (1L) therapy for patients with HR+/HER2− MBC. Novel therapies have demonstrated impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Shor, Anastasiya, Tremblay, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942396/
https://www.ncbi.nlm.nih.gov/pubmed/29765249
http://dx.doi.org/10.2147/CMAR.S162714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942396/
https://www.ncbi.nlm.nih.gov/pubmed/29765249
http://dx.doi.org/10.2147/CMAR.S162714

Ejemplares similares